• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

novice needs a straight answer

Anonymous

Guest
Mr. IMS:

In a nutshell, can someone explain to me how many standard data programs are available for a pharma company to buy. For instance, we all know there is a cost associated with the accuracy, however, is there a all-data program vs the comprehensive package, vs the cut rate package? Can some explain this in 3 sentences? Thank you.